Premium
Plasmapheresis and pregnancy outcome in patients with antiphospholipid syndrome
Author(s) -
ElHaieg D.O.,
Zanati M.F.,
ElFoual F.M.
Publication year - 2007
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1016/j.ijgo.2007.05.045
Subject(s) - medicine , plasmapheresis , antiphospholipid syndrome , prednisone , pregnancy , obstetrics , live birth , gestation , umbilical artery , eclampsia , lupus anticoagulant , hellp syndrome , gynecology , surgery , thrombosis , immunology , antibody , biology , genetics
Objective To assess plasmapheresis with low dose prednisone on obstetric and neonatal outcomes among unsuccessfully treated pregnant women with documented antiphospholipid syndrome (APS). Methods Eighteen pregnant women received prednisone (10 mg/day) and plasmapheresis at 7.08 ± 0.6 weeks of gestation, for 3 sessions per week, until lupus anticoagulant activity suppressed and IgG anticardiolipin lowered. Serial pulsatility indexes (PI) of umbilical and uterine arteries were performed. Results The live birth rate was 100%; mild pre‐eclampsia 5.5%; preterm deliveries 22.22%; intrauterine growth restriction 11.11%; thrombocytopenia 5.5%; oligohydramnios and fetal distress 16.6%. There were no perinatal deaths, thrombotic events or lupus flare. Uterine artery PI was reduced and umbilical artery PI was > 95th percentile. Conclusion Plasmapheresis and low dose prednisone were associated with a low rate of obstetric and neonatal complications. Plasmapheresis may be used to treat pregnant women with documented APS when first lines (aspirin and/or heparin) fail to prevent pregnancy loss.